Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients [Clinical Sciences]
Conclusions—
All the newer oral anticoagulants compared were more effective than adjusted dosed warfarin. Our model showed that apixaban was the most effective anticoagulant in a general atrial fibrillation population and has an incremental cost-effectiveness ratio <$50 000/QALY. For those with higher stroke risk (CHADS2≥3), dabigatran was the most cost-effective treatment option.
Source: Stroke - Category: Neurology Authors: Shah, A., Shewale, A., Hayes, C. J., Martin, B. C. Tags: Anticoagulants, Cost-Effectiveness, Ischemic Stroke Clinical Sciences Source Type: research
More News: Atrial Fibrillation | Cardiology | Clinical Trials | Congestive Heart Failure | Coumadin | Diabetes | Diabetes Mellitus | Endocrinology | Heart | Heart Failure | Hypertension | Insurance | Ischemic Stroke | Neurology | Pradaxa | Stroke | Study | Warfarin